Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 6/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23440307 | 0.97 | CYP1A1 (0.44) | CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43 | |
| SCHEMBL23440302 | 0.87 | CYP1A1 (0.40) | CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43 | |
| SCHEMBL23440270 | 0.84 | CYP2D6 (0.42) | CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43 | |
| SCHEMBL29983929 | 0.83 | CYP1A1 (0.52) | CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43 | |
| SCHEMBL26322241 | 0.78 | GPR35 (0.47) | CA12CA1CA2CA9GPR35 | |
| SCHEMBL23472064 | 0.78 | SLC26A3 (0.42) | CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43 | |
| SCHEMBL23471908 | 0.76 | KDM4E (0.42) | CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43 | |
| SCHEMBL23472098 | 0.75 | CYP1A1 (0.44) | CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43 | |
| SCHEMBL23472052 | 0.73 | CYP1A1 (0.43) | CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43 | |
| SCHEMBL12514970 | 0.71 | CA12 (0.55) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104758-A1 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH ZURICH (CH) | 2023-04-06 | — | — | US | disclosed |
| EP-4069684-A2 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH Zurich (CH) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021110834-A2 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH ZURICH (CH) | 2021-06-10 | — | — | WO | disclosed |
| EP-3831820-A1 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH Zurich (CH) | 2021-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104758-A1 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | DAO, LOX, AOC2 | CYP1A1 274/4885CYP2D6 494/4885CYP2B6 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.